Business context and reporting period
The supplied filing is HC2 Holdings, Inc.’s Form 10-K for the fiscal year ended December 31, 2020, filed March 10, 2021—not a quarterly filing. This differs from the request metadata naming INNOVATE Corp. The filing describes a diversified holding company with Infrastructure, Life Sciences, Spectrum, Insurance and Other operations. HC2 said it expected to focus on Infrastructure, Life Sciences and Spectrum.
Financial performance and liquidity
| Metric | 2020 | 2019 |
|---|---|---|
| Net revenue | $1,005.8 million | $1,077.0 million |
| Operating income (loss) | $(4.1) million | $25.3 million |
| Loss from continuing operations | $(38.3) million | $(22.2) million |
| Net loss attributable to HC2 | $(92.0) million | $(31.5) million |
| Net loss attributable to common and participating preferred holders | $(95.6) million | $(31.5) million |
| Operating cash flow, continuing operations | $52.4 million | $53.2 million |
| Operating cash flow, including discontinued operations | $41.7 million | $110.7 million |
| Capital expenditures | $17.8 million | $24.7 million |
| Cash and cash equivalents, consolidated | $232.3 million | $193.7 million |
| Debt obligations, consolidated carrying value | $561.5 million | $723.9 million |
Consolidated net revenue declined $71.2 million, or about 6.6%. The operating result moved from income to a loss. The company reported $25.5 million of Adjusted EBITDA, down from $43.4 million; this non-GAAP measure excludes the Insurance segment and should not be viewed as a substitute for GAAP results. No consolidated gross margin is clearly presented in the filing text.
At year-end, HC2 had $27.5 million of cash at the parent-company level and $188.5 million in the Insurance segment. HC2’s standalone debt included $340.4 million of 11.50% senior secured notes due December 2021, $55.0 million of 7.50% convertible notes due June 2022, and a fully drawn $15.0 million revolving facility. The company reported compliance with applicable debt covenants at December 31, 2020, but noted that future compliance could depend on refinancing, asset sales, capital raising or other transactions.
Segments and changes versus 2019
- Infrastructure: Revenue fell to $676.6 million from $713.3 million; operating income declined to $20.5 million from $45.1 million. Lower structural-steel activity and less power and industrial maintenance work were cited. Adjusted EBITDA decreased to $63.2 million from $75.7 million. Year-end backlog was $394.5 million, down from $497.7 million; five projects represented 35.9% of backlog.
- Life Sciences: Operating loss widened to $16.9 million from $8.9 million, reflecting higher R2 commercialization and development spending. Adjusted EBITDA loss increased to $22.5 million from $11.8 million.
- Spectrum: Revenue decreased to $40.3 million from $41.8 million, mainly due to weaker Azteca advertising during COVID-19. Operating loss narrowed to $2.2 million from $11.4 million, supported by cost reductions and station-sale gains. Adjusted EBITDA loss improved to $1.2 million from $6.3 million.
- Insurance: Revenue declined to $300.2 million from $331.6 million; operating income was $35.6 million versus $37.3 million. Lower net investment income and investment-market losses were partly offset by the absence of the prior-year $47.3 million goodwill impairment. Policy benefits, reserve changes and commissions rose to $250.0 million from $234.4 million. Long-term-care reserves were $4,269.0 million at year-end.
Outlook, material events and risks
Management said it believed available cash, subsidiary distributions and asset monetizations could meet liquidity needs for at least the next 12 months, while acknowledging that subsidiary distributions and asset sales are restricted and future financing on acceptable terms is not assured. The filing provides no formal revenue or earnings guidance. COVID-19 impacts included $19.4 million of Infrastructure-related costs, project and labor disruption risks, weaker Spectrum advertising and uncertainty around Life Sciences trials and launches. Management said the pandemic could materially affect future revenue growth and profitability, but that future impacts could not be reliably estimated.
HC2 received approximately $100.8 million of net proceeds from the February 2020 GMSL sale and $85.5 million in cash from the first tranche of the HMN stake sale, recognizing a $71.1 million gain on the latter. The GMSL sale resulted in a $39.3 million loss, including $31.3 million of AOCI realization; the company later recorded a $2.4 million gain related to a bonding-facility release. ICS was sold in October 2020, and Beyond6 was sold on January 15, 2021. Proceeds supported debt reduction and general corporate purposes. HC2 reported a $9.4 million early-extinguishment or restructuring loss in 2020.
After year-end, on February 1, 2021, HC2 issued $330.0 million of 8.50% senior secured notes due 2026 and used the proceeds, together with Beyond6 sale proceeds, to redeem the 11.50% notes, repay the revolving facility and cover related costs and general purposes. On February 23, 2021, the revolving facility was amended to a $20.0 million commitment and extended to February 2024. Other key risks include high leverage and interest costs, dependence on subsidiary distributions, construction project estimating and backlog concentration, insurance reserve assumptions and rate approvals, reinsurer credit exposure, investment valuation and interest-rate risk, and regulatory, litigation and execution risks. The filing identifies stockholder litigation concerning DBMG-related transactions, a former employee’s OSHA whistleblower complaint and arbitration involving former CEO Philip Falcone; management disputes the allegations and says it will defend the matters.
Important facts for investors to verify
- Confirm the issuer: the provided document is HC2 Holdings, Inc.’s 2020 annual report, not a filing identified as INNOVATE Corp.
- Review the refinancing terms and whether post-filing transactions resolved near-term maturities, covenant pressure and parent-company liquidity needs.
- Assess the quality and sustainability of cash generation, including the distinction between continuing and discontinued operations and reliance on asset-sale proceeds and subsidiary distributions.
- Examine Infrastructure backlog conversion, project concentration, cost estimates and COVID-19 effects; backlog is not guaranteed revenue or profit.
- Review Insurance reserve adequacy, planned long-term-care premium increases, statutory capital requirements, reinsurance collectability and the valuation of Level 3 investments.
- Consider equity dilution and preferred-stock rights: the 2020 rights offering raised approximately $61.5 million net, and common shares outstanding increased substantially.
- Note that the auditor gave an unqualified opinion on the financial statements and internal controls, while identifying contract cost-to-complete estimates, investment valuations and long-term-care reserve assumptions as critical audit matters.